Silverarc Capital Management, LLC 13F holdings, Q4 2024
Holdings as of December 31, 2024 · filings on SEC EDGAR · latest filing →
Silverarc Capital Management, LLC disclosed 58 US equity positions worth $447.2m in its Q4 2024 13F filing. The largest position was NUVALENT INC at 7.0% of the reported book, followed by MERUS N V and INSM. Against the Q3 2024 filing, it opened 10 new positions, added to 29 and reduced 10 among the top 50 holdings.
What did Silverarc Capital Management, LLC own in Q4 2024? Top 50 positions
| # | Stock | Sector | Weight | Value | Shares | Δ shares | vs Q3 2024 |
|---|---|---|---|---|---|---|---|
| 1 | NUVALENT INC | 7.0% | $31.3m | 400,014 | 8% | added | |
| 2 | MERUS N V | 6.4% | $28.6m | 680,845 | 7% | added | |
| 3 | INSM INSMED INC | Healthcare | 5.7% | $25.7m | 372,230 | 7% | added |
| 4 | VRNA VERONA PHARMA PLC | 5.4% | $24.0m | 516,014 | 48% | added | |
| 5 | AKERO THERAPEUTICS INC | 4.6% | $20.6m | 739,563 | 16% | added | |
| 6 | VCYT VERACYTE INC | Healthcare | 4.5% | $19.9m | 503,281 | 7% | added |
| 7 | ERAS ERASCA INC | Healthcare | 4.2% | $18.9m | 7,543,901 | 9% | added |
| 8 | PLRX PLIANT THERAPEUTICS INC | Healthcare | 3.9% | $17.3m | 1,315,601 | – | new |
| 9 | SNDX SYNDAX PHARMACEUTICALS INC | Healthcare | 3.6% | $16.3m | 1,230,400 | 225% | added |
| 10 | RNAGBP AVIDITY BIOSCIENCES INC | 3.5% | $15.8m | 543,651 | 14% | added | |
| 11 | RYTM RHYTHM PHARMACEUTICALS INC | Healthcare | 3.4% | $15.3m | 273,896 | 7% | added |
| 12 | ITCIEUR INTRA-CELLULAR THERAPIES INC | 3.3% | $15.0m | 179,085 | 7% | added | |
| 13 | URGN UROGEN PHARMA LTD | Healthcare | 2.7% | $11.9m | 1,120,473 | 24% | added |
| 14 | CNTA CENTESSA PHARMACEUTICALS PLC | 2.2% | $10.0m | 598,952 | -20% | reduced | |
| 15 | KOD KODIAK SCIENCES INC | Healthcare | 2.2% | $9.9m | 1,000,000 | 100% | added |
| 16 | PSTXUSD POSEIDA THERAPEUTICS INC | 2.2% | $9.7m | 1,012,307 | -73% | reduced | |
| 17 | ORIC ORIC PHARMACEUTICALS INC | Healthcare | 2.1% | $9.5m | 1,178,300 | 7% | added |
| 18 | TELA TELA BIO INC | 2.1% | $9.3m | 3,065,649 | 173% | added | |
| 19 | SRRK SCHOLAR ROCK HLDG CORP | Healthcare | 1.8% | $7.9m | 183,243 | – | new |
| 20 | WVE WAVE LIFE SCIENCES LTD | Healthcare | 1.7% | $7.5m | 608,897 | -3% | reduced |
| 21 | COGT COGENT BIOSCIENCES INC | Healthcare | 1.6% | $7.2m | 921,137 | -25% | reduced |
| 22 | ASND ASCENDIS PHARMA A/S | Healthcare | 1.6% | $7.1m | 51,491 | 930% | added |
| 23 | IRON DISC MEDICINE INC | Healthcare | 1.6% | $7.0m | 110,381 | 6% | added |
| 24 | CLDX CELLDEX THERAPEUTICS INC NEW | Healthcare | 1.5% | $6.7m | 264,560 | 82% | added |
| 25 | ELUT ELUTIA INC | 1.5% | $6.7m | 1,782,271 | 8% | added | |
| 26 | BDSX BIODESIX INC | 1.5% | $6.6m | 4,332,281 | 22% | added | |
| 27 | GOSS GOSSAMER BIO INC | Healthcare | 1.2% | $5.6m | 6,171,847 | 9% | added |
| 28 | PRAX PRAXIS PRECISION MEDICINES I | Healthcare | 1.2% | $5.6m | 72,516 | 8% | added |
| 29 | HELIX ACQUISITION CORP II | 1.2% | $5.4m | 513,369 | 0% | held | |
| 30 | RARE ULTRAGENYX PHARMACEUTICAL IN | Healthcare | 1.2% | $5.2m | 124,388 | – | new |
| 31 | 4XC1 KALVISTA PHARMACEUTICALS INC | 1.2% | $5.2m | 612,173 | 7% | added | |
| 32 | TVTX TRAVERE THERAPEUTICS INC | Healthcare | 1.1% | $4.8m | 277,365 | – | new |
| 33 | CCCC C4 THERAPEUTICS INC | Healthcare | 1.0% | $4.4m | 1,221,131 | 6% | added |
| 34 | GPCR STRUCTURE THERAPEUTICS INC | Healthcare | 0.9% | $4.1m | 152,395 | 116% | added |
| 35 | TARS TARSUS PHARMACEUTICALS INC | Healthcare | 0.8% | $3.7m | 65,955 | 65% | added |
| 36 | INCY INCYTE CORP | Healthcare | 0.8% | $3.4m | 49,000 | – | new |
| 37 | PCVX VAXCYTE INC | Healthcare | 0.7% | $3.3m | 40,788 | -33% | reduced |
| 38 | GERN GERON CORP | Healthcare | 0.7% | $3.3m | 920,022 | -49% | reduced |
| 39 | TRVI TREVI THERAPEUTICS INC | Healthcare | 0.7% | $3.0m | 734,234 | 52% | added |
| 40 | CGEN COMPUGEN LTD | Healthcare | 0.6% | $2.5m | 1,624,377 | 8% | added |
| 41 | CERS CERUS CORP | Healthcare | 0.5% | $2.4m | 1,587,228 | 6% | added |
| 42 | ABVX ABIVAX SA | 0.5% | $2.1m | 285,120 | -38% | reduced | |
| 43 | UNCY UNICYCIVE THERAPEUTICS INC | 0.4% | $2.0m | 2,486,709 | -38% | reduced | |
| 44 | VRDN VIRIDIAN THERAPEUTICS INC | Healthcare | 0.4% | $1.9m | 100,000 | – | new |
| 45 | DCTH DELCATH SYS INC | 0.4% | $1.9m | 155,325 | – | new | |
| 46 | QURE UNIQURE NV | 0.4% | $1.8m | 100,000 | – | new | |
| 47 | MODULAR MED INC | 0.4% | $1.7m | 1,272,015 | -12% | reduced | |
| 48 | KALA KALA BIO INC | 0.4% | $1.6m | 231,070 | – | new | |
| 49 | OLMA OLEMA PHARMACEUTICALS INC | Healthcare | 0.3% | $1.4m | 233,281 | -49% | reduced |
| 50 | GILD GILEAD SCIENCES INC | Healthcare | 0.2% | $923.7k | 10,000 | – | new |
Weights are shares of the reported long US equity book (options excluded). Values are as filed, normalised to whole dollars. Share changes compare against the immediately preceding filing only.